Is Cabozantinib currently available for purchase through formal channels in China?

As of now, cabozantinib has not been officially launched in mainland China, so patients in China cannot directly purchase this drug through formal channels. Since cabozantinib is an important multi-target tyrosine kinase inhibitor mainly used to treat tumors such as advanced renal cell carcinoma and hepatocellular carcinoma, many patients are in urgent need of this drug to obtain better therapeutic effects. In this regard, patients can obtain cabozantinib through regulated overseas channels to meet their treatment needs.

In overseas markets, the original drug cabozantinib has multiple versions, including European version, Hong Kong version, Japanese version and Turkish version. The price of these versions is higher, usually between more than 20,000 yuan to more than 50,000 yuan, and the price difference is mainly affected by regional policies, drug specifications and supply conditions. Although the price is higher, the original drug has a strong guarantee in terms of efficacy and safety, and is the first choice of many patients.

At the same time, countries such as Laos and Bangladesh have officially launched generic versions of cabozantinib. The ingredients of these generic drugs are basically the same as those of the original drug, ensuring the reliability of the drug's efficacy. Generic drugs come in various specifications, including 20 mg 90 tablets, 60 mg 30 tablets, 80 mg x 30 tablets, etc. The price is significantly lower than the original drug. The latest selling price is generally between more than 500 yuan to more than 1,000 yuan, which greatly reduces the financial burden of patients.
Overall, although cabozantinib has not yet been officially launched in China, patients can still purchase original drugs or generic drugs through compliant overseas channels. Patients should reasonably choose suitable drug specifications and versions based on their own condition and economic situation, while ensuring that the purchase channels are formal and avoid purchasing fake and shoddy drugs. In the future, with the advancement of drug approval in China, cabozantinib is expected to be launched in China, further facilitating patients' medication needs.
Reference: https://www.drugs.com/